2020—2023年郑州市重组带状疱疹疫苗疑似预防接种异常反应监测  

Surveillance of adverse events following of recombinant zoster vaccine immunization in Zhengzhou City from 2020 to 2023

作　　者：范张洁 史鲁斌 李锋[1] 王小丽 原宏 孟庆玉[1] 王雨润 王瑞 许海燕 韩吉楠 王萌[1] 乔丹 FAN Zhangjie;SHI Lubin;LI Feng;WANG Xiaoli;YUAN Hong;MENG Qingyu;WANG Yurun;WANG Rui;XU Haiyan;HAN Jinan;WANG Meng;QIAO Dan(Zhengzhou Center for Disease Control and Prevention,Zhengzhou,Henan 450007,China;Henan Center for Disease Control and Prevention)

机构地区：[1]郑州市疾病预防控制中心免疫规划所,河南郑州450007 [2]河南省疾病预防控制中心

出　　处：《现代疾病预防控制》2025年第3期201-205,239,共6页MODERN DISEASE CONTROL AND PREVENTION

摘　　要：目的对2020—2023年郑州市≥50岁人群接种重组带状疱疹疫苗后出现疑似预防接种异常反应的发生特征进行分析。方法通过中国疾病预防控制信息系统以及河南省免疫规划信息管理系统,收集2020—2023年郑州市16个区县(市)报告的重组带状疱疹疫苗疫苗疑似预防接种异常反应(AEFI)个案信息与接种剂次数据,采用描述性流行病学方法进行分析。结果2020—2023年郑州市共接种重组带状疱疹疫苗35120剂次,报告AEFI个案110例,年均报告发生率为313.21/10万剂,其中一般反应108例(307.52/10万剂),偶合症2例(5.69/10万剂)。一般反应中以发热、红肿、乏力、硬结和肌痛较为常见。郑州市16个区县(市)中巩义市报告发生率最高,为917.43/10万剂,其次为金水区(615.56/10万剂)。女性报告发生率340.09/10万剂,男性258.69/10万剂,50~<60岁组报告发生率为360.29/10万剂,60~<70岁组为254.32/10万剂,≥70岁组为220.26/10万剂。第二季度报告发生率394.71/10万剂。不同性别、不同年龄组别、不同季度间的报告发生率,差异均无统计学意义(χ^(2)值分别为1.649、3.604、4.018,P均>0.05)。第1剂报告发生率(387.99/10万剂)高于第2剂(218.90/10万剂),不同剂次间报告发生率差异有统计学意义(χ^(2)=7.933,P<0.05)。110例个案中98.18%转归为治愈、1.82%治疗。结论2020—2023年郑州市报告的重组带状疱疹疫苗疑似预防接种异常反应以一般反应为主,主要表现为发热、红肿、乏力、硬结和肌痛,无严重不良反应的报告,安全性良好。Objective The study aims to analyze the incidence of adverse events following immunization(AEFI)associated with recombinant zoster vaccine(RZV)administrated in Zhengzhou City from 2020 to 2023.Methods AEFI data for RZV from 2020 to2023 in Zhengzhou City were collected through China Disease Prevention and Control Information System.RZV administration data were obtained from Henan Provincial Immunization Program Information Management System.A descriptive epidemiological study was conducted to analyze the data.Results A total of 35120 doses of RZV were administered in Zhengzhou from 2020 to2023,with 110 AEFI cases reported.The annual average reported incidence of AEFI after RZV vaccination was 313.21 per 100000doses.There were 108 cases of general reaction and 2 cases of coupling disease,qith reported incidence of 307.52 per 100000doses and 5.69 per 100000 doses,respectively.Common symptoms included fever,redness,fatigue,sclerosis,and myalgia.Among the 16 districts and counties(cities)in Zhengzhou,Gongyi City reported the highest incidence rate(917.43 per 100000 doses),followed by Jinshui District(615.56 per 100000 doses).The reported incidence was higher in women(340.09 per 100000 doses)than in men(258.69 per 100000 doses).The reported incidence was the highest in the 50-<60 age group(360.29 per 100000doses),followed by the 60-<70 age group(254.32 per 100000 doses)and the 70 and older age group(220.26 per 100000 doses).The reported incidence rate was the highest in the second quarter(394.71 per 100000 doses).The reported incidence was higher for the first dose(387.99 per 100000 doses)compared to the second dose(218.90 per 100000 doses).There was no statistical significance in reported incidence among different genders,age groups,or quarters(χ^(2)=1.649,3.604,4.018,all P>0.05).However,a significant difference was observed between different doses(χ^(2)=7.933,P<0.05).Among 110 cases,98.18%were cured,and 1.82%were treated.Conclusions The AEFI reported for RZV in Zhengzhou from 2020 to 2023 were predominantly general

关 键 词：重组带状疱疹疫苗 疑似预防接种异常反应 特征 

分 类 号：R186[医药卫生—流行病学]